



### Company Overview

Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sale of innovative treatments and therapies, including those in the rare and orphan disease categories.

### Emmaus Life Sciences Reports Preliminary Gross Sales for the Three Months Ended September 30, 2019

Oct 11 2019, 8:00 AM EDT

### Emmaus Life Sciences Granted Patent in India for use of Pharmaceutical-grade L-glutamine in Treating Diverticulosis

Oct 9 2019, 7:30 AM EDT

### Emmaus Life Sciences Announces its Common Stock to Begin Trading on OTCQB September 26

Sep 26 2019, 8:00 AM EDT

### Stock Overview

Symbol	EMMA
Exchange	OTCQB
Market Cap	99.68m
Last Price	\$2.10
52-Week Range	\$1.33 - \$12.90

10/11/2019 02:52 PM EDT

### Investor Relations

PondelWilkinson Inc.  
Roger Pondel / Laurie Berman  
T: 310-279-5980  
[EMMA@pondel.com](mailto:EMMA@pondel.com)

### Management Team

#### Yutaka Niihara, MD, MPH

Chief Executive Officer, Chairman of the Board

#### Willis C. Lee

Chief Operating Officer, Vice-Chairman of the Board

#### Yasushi Nagasaki, CPA

Senior Vice President of Finance

#### George Sekulich

Senior Vice President of Global Commercialization and Chief Information Officer

#### Joseph (Jay) C. Sherwood III

Chief Financial Officer

#### Dale E. Short

General Counsel

#### Charles W. Stark, PharmD

Senior Vice President of Research and Development

#### Lan T. Tran

President, Chief Administrative Officer

### Emmaus Life Sciences, Inc.

21250 Hawthorne Blvd.  
Suite 800  
Torrance, CA 90503

### Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.